- Home
- SRZN vs INO Comparison
SRZN vs INO Comparison
Compare SRZN & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- INO
- Stock Information
- Founded
- SRZN 2015
- INO 1979
- Country
- SRZN United States
- INO United States
- Employees
- SRZN N/A
- INO N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- INO Medical/Dental Instruments
- Sector
- SRZN Health Care
- INO Health Care
- Exchange
- SRZN Nasdaq
- INO Nasdaq
- Market Cap
- SRZN 120.0M
- INO 136.6M
- IPO Year
- SRZN N/A
- INO 1998
- Fundamental
- Price
- SRZN $13.06
- INO $2.50
- Analyst Decision
- SRZN Strong Buy
- INO Buy
- Analyst Count
- SRZN 2
- INO 5
- Target Price
- SRZN $38.50
- INO $8.80
- AVG Volume (30 Days)
- SRZN 38.1K
- INO 1.1M
- Earning Date
- SRZN 11-07-2025
- INO 11-10-2025
- Dividend Yield
- SRZN N/A
- INO N/A
- EPS Growth
- SRZN N/A
- INO N/A
- EPS
- SRZN N/A
- INO N/A
- Revenue
- SRZN $12,621,000.00
- INO $182,337.00
- Revenue This Year
- SRZN N/A
- INO N/A
- Revenue Next Year
- SRZN N/A
- INO $14,751.49
- P/E Ratio
- SRZN N/A
- INO N/A
- Revenue Growth
- SRZN N/A
- INO N/A
- 52 Week Low
- SRZN $5.90
- INO $1.30
- 52 Week High
- SRZN $18.17
- INO $5.80
- Technical
- Relative Strength Index (RSI)
- SRZN 45.71
- INO 54.47
- Support Level
- SRZN $13.42
- INO $2.21
- Resistance Level
- SRZN $14.38
- INO $2.67
- Average True Range (ATR)
- SRZN 0.42
- INO 0.15
- MACD
- SRZN -0.12
- INO -0.01
- Stochastic Oscillator
- SRZN 5.63
- INO 62.98
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.